TCN 202
Alternative Names: TCN-202Latest Information Update: 05 Jun 2014
At a glance
- Originator Theraclone Sciences
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Simplexvirus glycoprotein B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cytomegalovirus infections
Most Recent Events
- 05 Jun 2014 Development has been discontinued for Cytomegalovirus infections
- 11 Sep 2013 Final adverse events data from a phase I trial in Cytomegalovirus infections (in volunteers) presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2013)
- 10 Sep 2013 Phase-II clinical trials in Cytomegalovirus infections (prevention) in Brazil (IV)